1
|
Bocquel S, Soria A, Raison-Peyron N, Badaoui A, Marcant P, Bara C, Giordano-Labadie F, Amsler E, Milpied B, Delaunay J, Darrigade AS, Pralong P, Boulard C, Ferrier Le Bouedec MC, Tauber M, Pasteur J, Valois A, Le Thuaut A, Crépy MN, Bernier C. Impact of dupilumab on patch test results and allergic contact dermatitis: A prospective multicenter study. J Am Acad Dermatol 2024; 90:512-520. [PMID: 37871801 DOI: 10.1016/j.jaad.2023.10.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Revised: 10/13/2023] [Accepted: 10/17/2023] [Indexed: 10/25/2023]
Abstract
BACKGROUND Limited and conflicting data have been reported on the impact of dupilumab (DUPI) on patch test (PT) results and its efficacy against allergic contact dermatitis (ACD). OBJECTIVE This study was undertaken to analyze PT reactivities and relevance during treatment with DUPI to determine whether they could detect ACD in patients with uncontrolled or worsened atopic dermatitis (AD) who were receiving this agent. METHODS This prospective, multicenter study examined 76 DUPI-treated patients who had undergone PTs. The relevant information was collected during 3 visits. RESULTS Overall, 36 patients (47%) had ≥1 positive PT reaction, and 142 PT results were positive. Twenty-three patients (30%) had ≥1 positive and clinically relevant PT result. Five of them had clinical eczema improvement after allergen avoidance. We compared the PT results of 36 patients before and during DUPI therapy, representing 1230 paired PT allergens, of which 1022 were the same, 34 were positive, 44 were lost, and 130 were uninterpretable. LIMITATIONS Because the number of patients included remains limited, our findings should be confirmed with a larger sample. CONCLUSION Our results confirmed the usefulness of PTs for patients receiving DUPI, with good PT reproducibility. We suggest that all DUPI-treated patients with AD developing partial responses or experiencing symptom worsening should undergo PTs to look for contact sensitization.
Collapse
Affiliation(s)
- Sarah Bocquel
- Department of Dermatology, Nantes University Hospital, Nantes, France
| | - Angèle Soria
- Médecine Sorbonne Université, Service de Dermatologie et d'Allergologie, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris (AP-HP), Dermatology and allergy department, Tenon hospital, AP-HP, Paris, France
| | | | - Antoine Badaoui
- Department of Dermatology, Hôpital d'Instruction des Armées Bégin, Saint-Mandé, France
| | | | - Corina Bara
- Department of Dermatology, CH Le Mans, Le Mans, France
| | | | - Emmanuelle Amsler
- Médecine Sorbonne Université, Service de Dermatologie et d'Allergologie, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris (AP-HP), Dermatology and allergy department, Tenon hospital, AP-HP, Paris, France
| | - Brigitte Milpied
- Department of Dermatology, Hôpital Saint-André, Bordeaux, France
| | | | | | | | - Claire Boulard
- Department of Dermatology, CH Jacques-Monod, Le Havre, France
| | | | - Marie Tauber
- Department of Dermatology, CHU Toulouse, Toulouse, France
| | - Justine Pasteur
- Department of Dermatology, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Aude Valois
- Department of Dermatology, HIA, Toulon, France
| | | | - Marie-Noëlle Crépy
- Department of Occupational and Environmental Diseases, Hôtel-Dieu Hospital, Paris, France
| | - Claire Bernier
- Department of Dermatology, Nantes University Hospital, Nantes, France.
| |
Collapse
|
2
|
Litovsky J, Hacard F, Tétart F, Boccon-Gibod I, Soria A, Staumont-Sallé D, Doutre MS, Amsler E, Mansard C, Dezoteux F, Darrigade AS, Milpied B, Bernier C, Perrot JL, Raison-Peyron N, Paryl M, Droitcourt C, Demoly P, Grosjean J, Mura T, Du-Thanh A. Omalizumab Drug Survival in Chronic Urticaria: A Retrospective Multicentric French Study. J Allergy Clin Immunol Pract 2023; 11:3752-3762.e2. [PMID: 37652349 DOI: 10.1016/j.jaip.2023.08.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 08/17/2023] [Accepted: 08/20/2023] [Indexed: 09/02/2023]
Abstract
BACKGROUND Omalizumab (OMA) dramatically improves disease control and quality of life in patients with chronic urticaria (CU). OBJECTIVE We aimed to evaluate the discontinuation patterns of OMA and their determinants in a cohort of French patients with CU. METHODS We conducted a retrospective multicenter study in 9 French tertiary referral hospitals. All patients diagnosed with either spontaneous (CSU) and/or inducible (CIndU) CU who received at least 1 injection of OMA between 2009 and 2021 were included. We analyzed OMA drug survival and investigated possible determinants using Kaplan-Meier curves and log-rank tests. RESULTS A total of 878 patients were included in this study; 48.8% had CSU, 10.1% CIndU, and 41.1% a combination of both. OMA was discontinued in 408 patients, but the drug was later reintroduced in 50% of them. The main reason for discontinuing treatment was the achievement of a well-controlled disease in 50% of patients. Half of the patients were still being treated with OMA 2.4 years after the initiation of treatment. Drug survival was shorter in patients with CIndU and in those with an autoimmune background. In atopic patients, OMA was discontinued earlier in patients achieving a well-controlled disease. A longer OMA drug survival was observed in patients with a longer disease duration at initiation. CONCLUSION In French patients with CU, the drug survival of OMA appears to be longer than that observed in previous studies conducted elsewhere, highlighting discrepancies in prescription and reimbursement possibilities. Further studies are warranted to develop customized OMA treatment schemes based on individual patterns.
Collapse
Affiliation(s)
- Julie Litovsky
- Département de Dermatologie, C.H.U de Montpellier, Montpellier, France
| | - Florence Hacard
- Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Allergologie et Immunologie Clinique, Pierre Bénite, France
| | - Florence Tétart
- Centre Erik Satie-Allergologie, Rouen University Hospital, Rouen, France
| | - Isabelle Boccon-Gibod
- Service de Médecine Interne, Centre National de Référence des Angioedèmes, CHU de Grenoble, Échirolles, France
| | - Angèle Soria
- Service de Dermatologie et Allergologie, Hôpital Tenon AP-HP, Sorbonne Université, Paris, France
| | - Delphine Staumont-Sallé
- CHU Lille, Service de Dermatologie, Université de Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE) F-59000, Lille, France
| | | | - Emmanuelle Amsler
- Service de Dermatologie et Allergologie, Hôpital Tenon AP-HP, Sorbonne Université, Paris, France
| | - Catherine Mansard
- Service de Médecine Interne, Centre National de Référence des Angioedèmes, CHU de Grenoble, Échirolles, France
| | - Frédéric Dezoteux
- CHU Lille, Service de Dermatologie, Université de Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE) F-59000, Lille, France
| | | | | | - Claire Bernier
- Plateforme Transversale d'Allergologie, Hôtel-Dieu-CHU de Nantes, Nantes, France
| | - Jean-Luc Perrot
- Service Dermatologie-Allergologie-Oncologie, CHU Nord Saint-Étienne U1059 INSERM, Saint-Priest-en-Jarez, France
| | | | - Marie Paryl
- Laboratoire de Biostatistiques, Épidémiologie, Santé Publique et Innovation Médicale Bespim, CHU De Nîmes, Nîmes, France
| | - Catherine Droitcourt
- Service de Dermatologie, CHU Rennes, Rennes, France; Université Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, Rennes, France
| | - Pascal Demoly
- Department of Allergology, University Hospital of Montpellier, Montpellier, France; IDESP UA11 University Montpellier, Montpellier, France
| | - Julien Grosjean
- Département d'Informatique BioMédicale, CHU de Rouen & LIMICS, U1142, Sorbonne Université, Paris, France
| | - Thibault Mura
- Laboratoire de Biostatistiques, Épidémiologie, Santé Publique et Innovation Médicale Bespim, CHU De Nîmes, Nîmes, France
| | - Aurélie Du-Thanh
- Département de Dermatologie, C.H.U de Montpellier, Montpellier, France.
| |
Collapse
|
3
|
Lejay S, Darrigade AS, Dupre D, Méry S, Verdu V, Stalder JF, Nosbaum A. Use of therapeutic patient education tools for atopic dermatitis: A French national survey. J Eur Acad Dermatol Venereol 2023; 37:e1271-e1273. [PMID: 37287185 DOI: 10.1111/jdv.19244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Accepted: 05/31/2023] [Indexed: 06/09/2023]
Affiliation(s)
- Solene Lejay
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service d'Allergologie et Immunologie Clinique, Pierre Benite, France
| | - Anne-Sophie Darrigade
- Dermatology, Department of Dermatology and Paediatric Dermatology, National Reference Centre for Rare Skin disorders, Univ. Bordeaux, INSERM, BMGIC, Bordeaux, France
| | - Dominique Dupre
- Dermatology Department, University Hospital of Brest, Brest, France
| | - Sophie Méry
- Pierre Fabre Eczema Foundation, Pierre Fabre Group, Toulouse, France
| | - Virginie Verdu
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service d'Allergologie et Immunologie Clinique, Pierre Benite, France
| | | | - Audrey Nosbaum
- Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Service d'Allergologie et Immunologie Clinique, Pierre Benite, France
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France
| |
Collapse
|
4
|
Lemery R, Cariou C, Darrigade AS, Rochefort-Morel C, Carvalho-Lallement P, Tedbirt B, Polard E, Picard S, Bergeron S, Sanchez-Pena P, Dupuy A, Triquet L, Droitcourt C. Immediate hypersensitivity to dupilumab: A French case series. J Allergy Clin Immunol Pract 2023; 11:2608-2610. [PMID: 37178761 DOI: 10.1016/j.jaip.2023.04.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/19/2022] [Revised: 03/27/2023] [Accepted: 04/20/2023] [Indexed: 05/15/2023]
Affiliation(s)
- Romain Lemery
- Dermatology Department, Rennes University Medical Center, Rennes, France
| | - Claire Cariou
- Dermatology Department, Rennes University Medical Center, Rennes, France; Department of Pulmonology and Allergology, Rennes University Medical Center, Rennes, France
| | | | - Cécile Rochefort-Morel
- Department of Pulmonology and Allergology, Rennes University Medical Center, Rennes, France
| | | | - Billal Tedbirt
- Dermatology Department, Rouen University Medical Center, Rouen, France
| | - Elisabeth Polard
- Regional Pharmacovigilance Center, Rennes University Medical Center, Rennes, France
| | - Sylvie Picard
- Regional Pharmacovigilance Center, Rennes University Medical Center, Rennes, France
| | - Sandrine Bergeron
- Regional Pharmacovigilance Center, Lille University Medical Center, Lille, France
| | - Paola Sanchez-Pena
- Regional Pharmacovigilance Center, Bordeaux University Medical Center, Bordeaux, France
| | - Alain Dupuy
- Dermatology Department, Rennes University Medical Center, Rennes, France; Univ Rennes, INSERM, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France
| | - Louise Triquet
- Regional Pharmacovigilance Center, Rennes University Medical Center, Rennes, France
| | - Catherine Droitcourt
- Dermatology Department, Rennes University Medical Center, Rennes, France; Univ Rennes, INSERM, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.
| |
Collapse
|
5
|
Clément A, Ferrier le Bouëdec MC, Crépy MN, Raison-Peyron N, Tétart F, Marcant P, Pralong P, Valois A, Pasteur J, Assier H, Bernier C, Le Cam MT, Hacard F, Nosbaum A, Giordano Labadie F, Morice C, Leleu C, Milpied B, Darrigade AS, Delaunay J, Barbaud A, Castelain F, Collet E, Amsler E. Hand eczema in glove-wearing patients. Contact Dermatitis 2023. [PMID: 37331721 DOI: 10.1111/cod.14357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 04/28/2023] [Accepted: 05/25/2023] [Indexed: 06/20/2023]
Abstract
BACKGROUND Allergic contact dermatitis to gloves is mostly induced by rubber accelerators. The European baseline series (EBS) appears insufficient to detect glove allergy. Since 2017, it is recommended to use the European rubber series (ERS) and to test the patients' own gloves. OBJECTIVES To investigate the clinical profile of glove-wearing patients with hand eczema (HE) and to evaluate their sensitisation profile to glove allergens and the value of testing the patients' own gloves. METHODS We conducted a French multicentre study of patients evaluated for HE between 2018 and 2020 and tested with the EBS, the ERS and their own gloves in patch tests and semi-open (SO) tests. RESULTS A total of 279 patients were included; 32.6% of patients had positive tests to their own gloves or to glove allergens. Almost 45% of the sensitisations to glove allergens were detected only by the ERS. Among the patients tested both in patch tests and SO tests with their own gloves with positive results, 28% had positive SO tests only. Polyvinylchloride (PVC) gloves were positive in four patients. CONCLUSION Our series confirms the need to test the ERS. All the patients' gloves must also be tested including PVC gloves. SO tests with gloves are useful as a complement to patch tests.
Collapse
Affiliation(s)
- Aude Clément
- Department of Dermatology, Hôpital Estaing, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | | | - Marie-Noëlle Crépy
- Department of Dermatology, Hôpital Cochin Port-Royal, APHP, Paris, France
| | - Nadia Raison-Peyron
- Department of Dermatology, Hôpital Saint Eloi, CHU Montpellier, Montpellier, France
| | - Florence Tétart
- Department of Allergology, Centre Erik Satie, CHU Rouen, Rouen, France
| | - Pierre Marcant
- Department of Dermatology, Hôpital Claude Huriez, CHU Lille, Lille, France
| | - Pauline Pralong
- Department of Dermatology, Hôpital Nord, CHU Grenoble, La Tronche, France
| | - Aude Valois
- Department of Dermatology, Hôpital d'instruction des armées Sainte Anne, Toulon, France
| | - Justine Pasteur
- Department of Dermatology, Hôpital Estaing, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Haudrey Assier
- Department of Dermatology, CHU Henri Mondor, Créteil, France
| | - Claire Bernier
- Department of Dermatology, Hôpital Hotel Dieu, CHU Nantes, Nantes, France
| | - Marie-Thérèse Le Cam
- Department of Professional Pathology, Centre hospitalier intercommunal, Créteil, France
| | - Florence Hacard
- Department of Allergology and Immunology, CHU Lyon sud, Lyon, France
| | - Audrey Nosbaum
- Department of Allergology and Immunology, CHU Lyon sud, Lyon, France
| | | | | | - Camille Leleu
- Department of Dermatology, CHU Dijon-Bourgogne, Dijon, France
| | - Brigitte Milpied
- Department of Dermatology, Hôpital Saint-André, CHU Bordeaux, Bordeaux, France
| | | | | | - Annick Barbaud
- Département de dermatologie et allergologie, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP.Sorbonne Université, Hôpital Tenon, Paris, France
| | - Florence Castelain
- Department of Dermatology, Hôpital Jean Minjoz, CHU Besançon, Besançon, France
| | - Evelyne Collet
- Department of Dermatology, CHU Dijon-Bourgogne, Dijon, France
| | - Emmanuelle Amsler
- Département de dermatologie et allergologie, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP.Sorbonne Université, Hôpital Tenon, Paris, France
| |
Collapse
|
6
|
Dupont A, Eyraud A, Milpied B, De Bataille S, Cassassa E, Darrigade AS, Barnetche T, Doutre MS, Matard B, Beylot-Barry M, Seneschal J. Efficacy and Safety of Tumour Necrosis Factor-α Antagonists for Folliculitis Decalvans: A Retrospective Case-series Pilot Study. Acta Derm Venereol 2023; 103:adv3713. [PMID: 36987539 PMCID: PMC10074284 DOI: 10.2340/actadv.v103.3713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2022] [Accepted: 12/16/2022] [Indexed: 03/30/2023] Open
Abstract
Folliculitis decalvans is a chronic inflammatory skin disease leading to scarring alopecia. Management of this disabling disease is difficult and no treatment is currently approved. Current knowledge regarding the pathogenesis of folliculitis decalvans suggests the benefit of using anti-tumour necrosis factor-α. This pilot study aimed to evaluate the clinical efficacy of anti-tumour necrosis factor-α for management of folliculitis decalvans. A single-centre retrospective pilot study included patients with refractory folliculitis decalvans treated by tumour necrosis factor-α inhibitors. An Investigator's Global Assessment (IGA) score was designed and validated to assess the efficacy of the therapy. Response to treatment was considered good to excellent when an IGA ≤ 2 was obtained at month 12. Eleven patients were included, with a mean time from diagnosis of folliculitis decalvans to the introduction of infliximab (n = 9) or adalimumab (n = 2) of 8.55 ± 1.26 years. Nine patients had failed on at least 2 lines of systemic therapies before starting anti-tumour necrosis factor-α. The median IGA score at baseline was 3. At the end of follow-up, 5 patients were considered responders. Overall, the safety profile of anti-tumour necrosis factor-α was good. The results suggest that the clinical benefit of anti-tumour necrosis factor-α is obtained after at least 6 months of treatment. However, further prospective studies are needed to confirm these results.
Collapse
Affiliation(s)
- Aurore Dupont
- Department of Dermatology, National Reference Center for Rare Skin Diseases, University Hospital of Bordeaux, Bordeaux, France
| | - Alexia Eyraud
- Department of Dermatology, Centre hospitalier de Périgueux, Périgueux, France
| | - Brigitte Milpied
- Department of Dermatology, National Reference Center for Rare Skin Diseases, University Hospital of Bordeaux, Bordeaux, France
| | | | - Eline Cassassa
- Department of Dermatology, Hôpital Larrey, Toulouse, France
| | - Anne-Sophie Darrigade
- Department of Dermatology, National Reference Center for Rare Skin Diseases, University Hospital of Bordeaux, Bordeaux, France
| | - Thomas Barnetche
- Department of Rheumatology, National Reference Center for Severe Systemic Autoimmune Diseases, FHU ACRONIM, University Hospital of Bordeaux, Bordeaux, France
| | - Marie-Sylvie Doutre
- Department of Dermatology, National Reference Center for Rare Skin Diseases, University Hospital of Bordeaux, Bordeaux, France
| | - Bruno Matard
- Centre Sabouraud, Hôpital Saint-Louis, Paris, France
| | - Marie Beylot-Barry
- Department of Dermatology, National Reference Center for Rare Skin Diseases, University Hospital of Bordeaux, Bordeaux, France; INSERM U1053, BaRITOn, Oncogenesis of cutaneous lymphomas Team, University of Bordeaux, Bordeaux, France
| | - Julien Seneschal
- Department of Dermatology, National Reference Center for Rare Skin Diseases, University Hospital of Bordeaux, Bordeaux, France; CNRS, UMR-5164, ImmunoConCept, F-33000, Bordeaux, France .
| |
Collapse
|
7
|
Du-Thanh A, Soria A, Amsler E, Badaoui A, Doutre MS, Gabison G, Bernier C, Staumont-Sallé D, Hacard F, Castelain F, Darrigade AS, Tapsoba GPML, Sarre ME, Mathelier-Fusade P, Delaunay J, Pralong P, Barbaud A, Dezoteux F, Trémeau-Martinage C, Bachtarzi Z, Augey F. Discrepancies in the management of acquired cold contact urticaria: Results of a French-speaking urticaria experts questionnaire survey. World Allergy Organ J 2022; 15:100688. [PMID: 36092949 PMCID: PMC9421398 DOI: 10.1016/j.waojou.2022.100688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Revised: 08/02/2022] [Accepted: 08/02/2022] [Indexed: 11/27/2022] Open
Abstract
Acquired cold contact urticaria (ACU) is a putatively serious condition, because of the risk of anaphylactic shock whenever patients are massively exposed to cold atmosphere/water, raising the question of the prescription of an “emergency kit” with oral antihistamines and epinephrine auto-injector. We performed an online survey to evaluate how French-speaking urticaria experts manage ACU. According to the 2016 consensus recommendations on chronic inducible urticarias, all the participants perform at least 1 of the available provocation tests and 84.2%, 77.8%, and 88.9% prescribe on-label use of second generation anti-H1 antihistamines (2GAH1) as a first line treatment, updosed 2GAH1 as a second line treatment, and omalizumab as a third line treatment, respectively. Interestingly, 44.4% of the practitioners always prescribe a continuous background treatment, versus 11.1% prescribing only on-demand therapy. Also, 11.7% of participants always prescribe an epinephrine auto-injector, 70.6% sometimes do, and 17.6% never do. Finally, 89.5% authorize swimming under strict conditions but 36.8% and 68.4% contra-indicate other water sports and occupational cold exposure, respectively.
Collapse
|
8
|
Franceschi J, Darrigade AS, Sanchez-Pena P, Legrain-Lifermann V, Milpied B. Pyoderma gangrenosum after mRNA-based SARS-CoV-2 vaccine. J Eur Acad Dermatol Venereol 2022; 36:e969-e970. [PMID: 35771124 PMCID: PMC9350046 DOI: 10.1111/jdv.18389] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- J Franceschi
- Department of Dermatology, Bordeaux University Hospital, France
| | - A S Darrigade
- Department of Dermatology, Bordeaux University Hospital, France
| | - P Sanchez-Pena
- Regional Center of Pharmacovigilance, Pharmacology Department, Bordeaux University Hospital, France
| | | | - B Milpied
- Department of Dermatology, Bordeaux University Hospital, France
| |
Collapse
|
9
|
Ingen-Housz-Oro S, Milpied B, Badrignans M, Carrera C, Elshot YS, Bensaid B, Segura S, Apalla Z, Markova A, Staumont-Sallé D, Marti-Marti I, Giavedoni P, Chua SL, Darrigade AS, Dezoteux F, Starace M, Torre AC, Riganti J, de Prost N, Lebrun-Vignes B, Bauvin O, Walsh S, Ortonne N, French LE, Sibaud V. Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases. Melanoma Res 2022; 32:205-210. [PMID: 35377864 PMCID: PMC9377568 DOI: 10.1097/cmr.0000000000000819] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Among dermatologic adverse events induced by immune checkpoint inhibitors (ICI), bullous life-threatening reactions are rare. To better define the clinical and histological features, treatment, and prognosis of ICI-related severe blistering cutaneous eruptions. This retrospective case series was conducted between 2014/05/15 and 2021/04/15 by the dermatology departments of four international registries involved in drug reactions. Inclusion criteria were age ≥18 years old, skin eruption with blisters with detachment covering ≥1% body surface area and at least one mucous membrane involved, available pictures, and ICI as suspect drug. Autoimmune bullous disorders were excluded. Each participant medical team gave his own diagnosis conclusion: epidermal necrolysis (EN), severe lichenoid dermatosis (LD), or unclassified dermatosis (UD). After a standardized review of pictures, cases were reclassified by four experts in EN or LD/UD. Skin biopsies were blindly reviewed. Thirty-two patients were included. Median time to onset was 52 days (3-420 days). Cases were originally diagnosed as EN in 21 cases and LD/UD in 11 cases. After review by experts, 10/21 EN were reclassified as LD/UD. The following manifestations were more frequent or severe in EN: fever, purpuric macules, blisters, ocular involvement, and maximal detachment. Most patients were treated with topical with or without systemic corticosteroids. Eight patients (25%) died in the acute phase. The culprit ICI was not resumed in 92% of cases. In three patients, another ICI was given with a good tolerance. Histology did not reveal significant differences between groups. Severe blistering cutaneous drug reactions induced by ICI are often overdiagnosed as EN. Consensus for management is pending.
Collapse
Affiliation(s)
- Saskia Ingen-Housz-Oro
- Dermatology department, AP-HP, Henri Mondor hospital, Créteil, France
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- FISARD group, Paris, France
- Univ Paris est Créteil EpidermE, Créteil, France
- European Task Force “Dermatology for cancer patients” of EADV
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
| | - Brigitte Milpied
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- FISARD group, Paris, France
- European Task Force “Dermatology for cancer patients” of EADV
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
- Dermatology department, CHU Bordeaux, Bordeaux, France
| | - Marine Badrignans
- Pathology department, AP-HP, Henri Mondor hospital, Créteil, France
- Université Paris Est Créteil Val de Marne UPEC, Créteil, France
| | - Cristina Carrera
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain
- CIBERER Centro de investigaciones Biomedicas en Red de Enfermedades Raras Insituto de Salud Carlos III, Spain
- Pharmacovigilance Technical Committee Hospital Clinic Barcelona, Spain
| | - Yannick S. Elshot
- European Task Force “Dermatology for cancer patients” of EADV
- Department of Dermatology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands
- Department of Dermatology, Amsterdam UMC, Univ. of Amsterdam, The Netherlands
| | - Benoit Bensaid
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- FISARD group, Paris, France
- Dermatology department, CHU Edouard Herriot, Lyon, France
| | - Sonia Segura
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital del Mar, Universitat Pompeu Fabra, Barcelona, Spain
| | - Zoé Apalla
- European Task Force “Dermatology for cancer patients” of EADV
- Second Dermatology Department, Medical School, Aristotle University of Thessaloniki, Greece
| | - Alina Markova
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Dermatology, Weill Cornell Medical College, New York, NY, USA
| | - Delphine Staumont-Sallé
- FISARD group, Paris, France
- Dermatology Department, CHU Lille, University Lille, INFINITE U1286 Inserm, Lille, France
| | - Ignasi Marti-Marti
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain
| | - Priscila Giavedoni
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain
| | - Ser-Ling Chua
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
- Department of Dermatology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
| | - Anne-Sophie Darrigade
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- FISARD group, Paris, France
- Dermatology department, CHU Bordeaux, Bordeaux, France
| | - Frédéric Dezoteux
- FISARD group, Paris, France
- Dermatology Department, CHU Lille, University Lille, INFINITE U1286 Inserm, Lille, France
| | - Michela Starace
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology -IRCCS Policlinico di Sant’Orsola - Department of Experimental, Diagnostic and Specialty Medicine (DIMES) Alma Mater Studiorum University of Bologna, Italy
| | - Ana Clara Torre
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - Julia Riganti
- European Task Force “Dermatology for cancer patients” of EADV
- Dermatology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
| | - Nicolas de Prost
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- Intensive care unit, AP-HP, Henri Mondor hospital, Créteil, France
| | - Bénédicte Lebrun-Vignes
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- FISARD group, Paris, France
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
- Regional Pharmacovigilance Center, AP-HP, Pitié-Salpêtrière hospital, Paris, France
| | - Olivia Bauvin
- FISARD group, Paris, France
- Dermatology department, CHU Charles Nicolle, Rouen, France
| | - Sarah Walsh
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
- Department of Dermatology, King’s College Hospital, London, United Kingdom
| | - Nicolas Ortonne
- Reference center for toxic bullous diseases and severe drug reactions TOXIBUL, Créteil, France
- Pathology department, AP-HP, Henri Mondor hospital, Créteil, France
- Université Paris Est Créteil Val de Marne UPEC, Créteil, France
| | - Lars E. French
- ToxiTEN group, European Reference Network for Rare Skin Diseases, Paris, France
- Department of Dermatology and Allergy, University Hospital, Ludwig Maximilan University (LMU) Munich, Munich, Germany
- Dr. Philip Frost, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL
| | - Vincent Sibaud
- European Task Force “Dermatology for cancer patients” of EADV
- Department of Oncodermatology, Claudius Regaud Institute and University Cancer Institute Toulouse Oncopole, Toulouse, France
| |
Collapse
|
10
|
Beaumont C, Darrigade AS, Barbaud A, Collet E, Raison-Peyron N, Bourrain JL, Assier H, Giordano-Labadie F, Bara-Passot C, Milpied B, Tétart F, Armingaud P, Castelain F, Benkalfate L, Boulard C, Delaunay J, Mathelier-Fusade P, Pecquet C, Pralong P, Vital-Durand D, Genillier Foin N, Lefèvre MA, Hacard F, Nosbaum A, Pasteur J, Valois A, Vigan M, Ferrier le Bouëdec MC. 102 cases of sensitization to an antiseptic containing chlorhexidine digluconate/benzalkonium chloride/benzyl alcohol with different profiles of sensitization in adults and children. Contact Dermatitis 2022; 87:62-70. [PMID: 35213760 DOI: 10.1111/cod.14085] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2021] [Revised: 02/09/2022] [Accepted: 02/10/2022] [Indexed: 11/30/2022]
Abstract
BACKGROUND An aqueous antiseptic containing "chlorhexidine digluconate /benzalkonium chloride /benzyl alcohol" (CBB) is widely used in France. The only previous documented study dealing with allergic contact dermatitis to this antiseptic is one small case series in children. The French Vigilance Network for Dermatology and Allergy (REVIDAL-GERDA) has collected many cases in the last few years. OBJECTIVES To evaluate the clinical and sensitization profiles of patients diagnosed with allergic contact dermatitis to CBB. METHODS We performed a retrospective study of patients with contact dermatitis to CBB and positive tests to CBB and/or at least one of its components. All patients had to be tested with all components of CBB. RESULTS Seventy-one adults and thirty-one children were included. The lesions were extensive in 63 % of patients and 55% had delayed time to diagnosis. CBB patch tests were positive in 93.8% of cases. The allergen was identified in 97% of patients, mainly benzyl alcohol in adults (81.7%), and chlorhexidine digluconate in children (54.8%). 32.4% of the patients were sensitized to several components. CONCLUSION CBB is a cause of allergic contact dermatitis at all ages. The antiseptic's components should be tested. The sensitization profile seems to be different between adults and children. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Charlotte Beaumont
- Department of Dermatology, Hôpital Estaing, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | | | - Annick Barbaud
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP.Sorbonne Université, Hôpital Tenon, Département de dermatologie et allergologie, Paris, France
| | - Evelyne Collet
- Department of Dermatology, CHU, Dijon-Bourgogne, Dijon, France
| | - Nadia Raison-Peyron
- Department of Dermatology, Hôpital Saint Eloi, CHU Montpellier, Montpellier, France
| | - Jean-Luc Bourrain
- Department of Pneumology and Allergology, CHU Montpellier, Montpellier, France
| | - Haudrey Assier
- Department of Dermatology, CHU Henri Mondor, Créteil, France
| | | | | | - Brigitte Milpied
- Department of Dermatology, Hôpital Saint-André, CHU Bordeaux, Bordeaux, France
| | - Florence Tétart
- Department of Allergology, Centre Erik Satie, CHU Rouen, Rouen, France
| | | | - Florence Castelain
- Department of Dermatology, Hôpital Jean Minjoz, CHU Besançon, Besançon, France
| | | | - Claire Boulard
- Department of Dermatology, Hôpital Jacques Monod, CH Le Havre, Montivilliers, France
| | | | - Pascale Mathelier-Fusade
- Sorbonne Université, AP-HP, Hôpital Tenon, Département de dermatologie et allergologie, Paris, France
| | - Catherine Pecquet
- Sorbonne Université, AP-HP, Hôpital Tenon, Département de dermatologie et allergologie, Paris, France
| | - Pauline Pralong
- Department of Dermatology, Hôpital Nord, CHU Grenoble, La Tronche, France
| | | | | | | | - Florence Hacard
- Department of Allergology and Immunology, CHU, Lyon sud, Pierre Bénite, France
| | - Audrey Nosbaum
- Department of Allergology and Immunology, CHU, Lyon sud, Pierre Bénite, France
| | - Justine Pasteur
- Department of Dermatology, Hôpital Estaing, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Aude Valois
- Department of Dermatology, Hôpital d'instruction des armées Sainte Anne, Toulon, France
| | - Martine Vigan
- Department of Dermatology, Hôpital Jean Minjoz, CHU Besançon, Besançon, France
| | | | | |
Collapse
|
11
|
Letertre O, Anii V, Jullie ML, Milpied B, Seneschal J, Darrigade AS. Linear immunoglobulin A bullous dermatosis associated with disseminated tuberculosis. Int J Dermatol 2021; 60:e361-e362. [PMID: 33742695 DOI: 10.1111/ijd.15526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2020] [Revised: 02/12/2021] [Accepted: 02/26/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Oriane Letertre
- Department of Dermatology, Hôpital Saint André, CHU de Bordeaux, France
| | - Veronica Anii
- Department of Internal Medicine, CH d'Arcachon, France
| | - Marie-Laure Jullie
- Department of Pathology, Hôpital du Haut Lévêque, CHU de Bordeaux, France
| | - Brigitte Milpied
- Department of Dermatology, Hôpital Saint André, CHU de Bordeaux, France
| | - Julien Seneschal
- Department of Dermatology, Hôpital Saint André, CHU de Bordeaux, France
| | | |
Collapse
|
12
|
de Montjoye L, Darrigade AS, Giménez-Arnau A, Herman A, Dumoutier L, Baeck M. Correlations between disease activity, autoimmunity and biological parameters in patients with chronic spontaneous urticaria. Eur Ann Allergy Clin Immunol 2021; 53:55-66. [PMID: 31965967 DOI: 10.23822/eurannaci.1764-1489.132] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Summary Background. Biomarkers of disease activity/severity and criteria of autoimmune chronic spontaneous urticaria (CSU) are still a matter of debate. Objective. To investigate possible correlations between clinical and biological markers and their associations with: 1) disease activity, 2) resistance to H1-antihistamines, 3) autoimmunity and 4) autologous serum skin test (ASST) in patients with CSU. To also analyze biological parameter modifications in patients with CSU treated with omalizumab. Materials and methods. Disease activity, H1-antihistamines response and presence of concomitant autoimmune disease were prospectively recorded in 95 patients with CSU. For 60 of them, ASST was performed. Broad biological analysis were performed. Results. C-reactive protein (CRP) serum levels were higher in H1-antihistamines unresponders (p less-than 0.0001) and in more active diseases (p = 0.033). D-dimer plasma levels were higher in H1-antihistamines unresponders (p = 0.008) and in patients with autoimmune status (concomitant autoimmune disease and/or with autoantibodies) (p = 0.016). Total immunoglobuline E (IgE) serum level was lower in patients with positive ASST. Blood basophil counts were lower in patients with CSU and especially in H1-antihistamines unresponders (p = 0.023), in patients with more active disease (p = 0.023), with positive ASST (p = 0.001), and with autoimmune status (p = 0.057). Conversely, under omalizumab, a decrease of CRP (p = 0.0038) and D-dimer serum/plasma levels (p = 0.0002) and an increase of blood basophil counts (p = 0.0023) and total IgE serum levels (p = 0.0007) were observed. Conclusions. This study brings additional evidences of interest to investigate IgE, D-dimer serum/plasma levels and basophil blood counts in patients with CSU as they could be correlated to disease activity, response to treatment and/or autoimmunity.
Collapse
Affiliation(s)
- L de Montjoye
- Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.,Institute of Experimental and Clinical Research, Pneumology, ENT and Dermatology Pole, Université catholique de Louvain, Brussels, Belgium
| | - A S Darrigade
- Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium
| | - A Giménez-Arnau
- Department of Dermatology, Hospital del Mar, Institut Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain
| | - A Herman
- Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.,Institute of Experimental and Clinical Research, Pneumology, ENT and Dermatology Pole, Université catholique de Louvain, Brussels, Belgium
| | - L Dumoutier
- de Duve Institute, Université catholique de Louvain, Brussels, Belgium
| | - M Baeck
- Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.,Institute of Experimental and Clinical Research, Pneumology, ENT and Dermatology Pole, Université catholique de Louvain, Brussels, Belgium
| |
Collapse
|
13
|
Renaudin H, Darrigade AS, Dendooven E, Foubert K, Aerts O, Milpied B. Allergic contact dermatitis from a disposable blood pressure cuff containing isobornyl acrylate and 2-phenoxyethyl acrylate. Contact Dermatitis 2021; 84:462-464. [PMID: 33320962 DOI: 10.1111/cod.13761] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Accepted: 12/04/2020] [Indexed: 11/30/2022]
Affiliation(s)
- Hélène Renaudin
- Department of Dermatology, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France
| | | | - Ella Dendooven
- Department of Dermatology, University Hospital Antwerp and Research group Immunology, Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium.,Research group Natural Products & Food - Research and Analysis (NatuRA), Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium
| | - Kenn Foubert
- Research group Natural Products & Food - Research and Analysis (NatuRA), Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium
| | - Olivier Aerts
- Department of Dermatology, University Hospital Antwerp and Research group Immunology, Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Brigitte Milpied
- Department of Dermatology, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France
| |
Collapse
|
14
|
Fauconneau A, Sokolowsky N, Camus M, Darrigade AS, Guillet S, Jullie ML, Beylot-Barry M, Doutre MS. Acquired cutis laxa associated with neutrophilic urticarial dermatosis. Int J Dermatol 2020; 60:771-772. [PMID: 33226126 DOI: 10.1111/ijd.15314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2020] [Revised: 10/18/2020] [Accepted: 10/22/2020] [Indexed: 11/30/2022]
Affiliation(s)
| | - Nina Sokolowsky
- Department of Dermatology, Hôpital Saint André, Bordeaux, France
| | | | | | | | | | | | | |
Collapse
|
15
|
Briand C, Gourier G, Poizeau F, Jelti L, Bachelerie M, Quéreux G, Jeudy G, Acquitter M, Ingen-Housz-Oro S, Caux F, Prost C, Darrigade AS, Heron Mermin D, Mahé E, Picart Dahan C, Richard MA, Clerc CJ, Salle De Chou C, Plée J, Abasq-Thomas C, Misery L, Brenaut E. Characteristics of Pruritus in Bullous Pemphigoid and Impact on Quality of Life: A Prospective Cohort Study. Acta Derm Venereol 2020; 100:adv00320. [PMID: 33135772 PMCID: PMC9309871 DOI: 10.2340/00015555-3683] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Pruritus is a common symptom of bullous pemphigoid (BP), but has been poorly studied. The aim of this study was to analyse the characteristics of pruritus in patients with BP and its impact on their quality of life. A multicentre prospective observational study (in 15 French hospitals) was performed. A total of 60 patients were included, with a mean age of 77.4 years. Pruritus occurred daily in 85% of patients, with a mean pruritus intensity of 5.2/10. Tingling sensations were present in 72.4% of patients and burning sensations in 68.9%. Pruritus was exacerbated by stress, fatigue and xerosis. The mean ItchyQol score was 56.2/110 and the mean 5-D Itch Scale score was 16.5/25. The severity of pruritus was not related to age, sex, BP activity score, eosinophilia, or anti-BP230 and anti-BP180 autoantibodies. This study revealed that pruritus in BP is poorly tolerated and is an important cause of impaired quality of life.
Collapse
Affiliation(s)
- Clémence Briand
- Department of Dermatology, Centre Hospitalier Universitaire (CHU) Brest, FR-29609 Brest, France. E-mail:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Darrigade AS, Dendooven E, Mangodt E, Aerts O. Delayed-type hypersensitivity to secukinumab with tolerance to ixekizumab. J Allergy Clin Immunol Pract 2020; 8:3626-3628. [PMID: 32585409 DOI: 10.1016/j.jaip.2020.06.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Revised: 06/03/2020] [Accepted: 06/05/2020] [Indexed: 12/23/2022]
Affiliation(s)
- Anne-Sophie Darrigade
- Department of Dermatology, Contact Allergy Unit, University Hospital Antwerp (UZA) and University of Antwerp (UA), Wilrijkstraat, Antwerp, Belgium
| | - Ella Dendooven
- Department of Dermatology, Contact Allergy Unit, University Hospital Antwerp (UZA) and University of Antwerp (UA), Wilrijkstraat, Antwerp, Belgium
| | - Evelyne Mangodt
- Department of Dermatology, Contact Allergy Unit, University Hospital Antwerp (UZA) and University of Antwerp (UA), Wilrijkstraat, Antwerp, Belgium
| | - Olivier Aerts
- Department of Dermatology, Contact Allergy Unit, University Hospital Antwerp (UZA) and University of Antwerp (UA), Wilrijkstraat, Antwerp, Belgium.
| |
Collapse
|
17
|
Darrigade AS, Dendooven E, Mangodt E, Van Dyck F, Aerts O. Airborne allergic contact dermatitis by proxy caused by 'poppers'. Contact Dermatitis 2020; 84:212-214. [PMID: 33044744 DOI: 10.1111/cod.13718] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Revised: 10/05/2020] [Accepted: 10/08/2020] [Indexed: 12/01/2022]
Affiliation(s)
- Anne-Sophie Darrigade
- Department of Dermatology, Contact Allergy Unit, University Hospital Antwerp (UZA), Antwerp, Belgium
| | - Ella Dendooven
- Department of Dermatology, Contact Allergy Unit, University Hospital Antwerp (UZA), Antwerp, Belgium.,Research Group Immunology, Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium
| | - Evelyne Mangodt
- Department of Dermatology, Contact Allergy Unit, University Hospital Antwerp (UZA), Antwerp, Belgium
| | | | - Olivier Aerts
- Department of Dermatology, Contact Allergy Unit, University Hospital Antwerp (UZA), Antwerp, Belgium.,Research Group Immunology, Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium
| |
Collapse
|
18
|
Boukhedouni N, Martins C, Darrigade AS, Drullion C, Rambert J, Barrault C, Garnier J, Jacquemin C, Thiolat D, Lucchese F, Morel F, Ezzedine K, Taieb A, Bernard FX, Seneschal J, Boniface K. Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. JCI Insight 2020; 5:133772. [PMID: 32369451 DOI: 10.1172/jci.insight.133772] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2019] [Accepted: 04/23/2020] [Indexed: 02/06/2023] Open
Abstract
Loss of melanocytes is the pathological hallmark of vitiligo, a chronic inflammatory skin depigmenting disorder induced by exaggerated immune response, including autoreactive CD8 T cells producing high levels of type 1 cytokines. However, the interplay between this inflammatory response and melanocyte disappearance remains to be fully characterized. Here, we demonstrate that vitiligo skin contains a significant proportion of suprabasal melanocytes, associated with disruption of E-cadherin expression, a major protein involved in melanocyte adhesion. This phenomenon is also observed in lesional psoriatic skin. Importantly, apoptotic melanocytes were mainly observed once cells were detached from the basal layer of the epidermis, suggesting that additional mechanism(s) could be involved in melanocyte loss. The type 1 cytokines IFN-γ and TNF-α induce melanocyte detachment through E-cadherin disruption and the release of its soluble form, partly due to MMP-9. The levels of MMP-9 are increased in the skin and sera of patients with vitiligo, and MMP-9 is produced by keratinocytes in response to IFN-γ and TNF-α. Inhibition of MMP-9 or the JAK/STAT signaling pathway prevents melanocyte detachment in vitro and in vivo. Therefore, stabilization of melanocytes in the basal layer of the epidermis by preventing E-cadherin disruption appears promising for the prevention of depigmentation occurring in vitiligo and during chronic skin inflammation.
Collapse
Affiliation(s)
- Nesrine Boukhedouni
- INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France
| | - Christina Martins
- INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France
| | - Anne-Sophie Darrigade
- INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France.,Department of Dermatology and Pediatric Dermatology and National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Bordeaux, France
| | - Claire Drullion
- INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France
| | | | | | | | - Clément Jacquemin
- INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France
| | - Denis Thiolat
- INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France
| | - Fabienne Lucchese
- INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France
| | - Franck Morel
- Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, University of Poitiers, Poitiers, France
| | - Khaled Ezzedine
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Hôpital Henri-Mondor, Créteil, France
| | - Alain Taieb
- Department of Dermatology and Pediatric Dermatology and National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Bordeaux, France
| | | | - Julien Seneschal
- INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France.,Department of Dermatology and Pediatric Dermatology and National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Bordeaux, France
| | - Katia Boniface
- INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers (BMGIC), Immunodermatology ATIP-AVENIR, University of Bordeaux, FHU ACRONIM, Bordeaux, France
| |
Collapse
|
19
|
Affiliation(s)
- Adeline Legrand
- Department of Dermatology, National Reference Center for Rare Skin Diseases, Bordeaux University Hospitals, Bordeaux, France
| | - Anne-Sophie Darrigade
- Department of Dermatology, National Reference Center for Rare Skin Diseases, Bordeaux University Hospitals, Bordeaux, France
| | - Alain Taieb
- Department of Dermatology, National Reference Center for Rare Skin Diseases, Bordeaux University Hospitals, Bordeaux, France.,INSERM U 1035, BMGIC, Immuno-Dermatology, ATIP-AVENIR, Bordeaux University, Bordeaux, France
| | - Brigitte Milpied
- Department of Dermatology, National Reference Center for Rare Skin Diseases, Bordeaux University Hospitals, Bordeaux, France
| | - Julien Seneschal
- Department of Dermatology, National Reference Center for Rare Skin Diseases, Bordeaux University Hospitals, Bordeaux, France.,INSERM U 1035, BMGIC, Immuno-Dermatology, ATIP-AVENIR, Bordeaux University, Bordeaux, France
| |
Collapse
|
20
|
Amico S, Barnetche T, Dequidt L, Fauconneau A, Gérard E, Boursault L, Boniface K, Darrigade AS, Seneschal J. Characteristics of postinflammatory hyper- and hypopigmentation in patients with psoriasis: A survey study. J Am Acad Dermatol 2020; 83:1188-1191. [PMID: 32068039 DOI: 10.1016/j.jaad.2020.02.025] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2019] [Revised: 02/03/2020] [Accepted: 02/06/2020] [Indexed: 11/28/2022]
Affiliation(s)
- Séverine Amico
- Department of Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Centre Hospitalo-Universitaire (CHU) de Bordeaux, Bordeaux, France
| | - Thomas Barnetche
- Department of Rheumatology, National Reference Center for Severe Systemic Autoimmune Diseases, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - Laure Dequidt
- Department of Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Centre Hospitalo-Universitaire (CHU) de Bordeaux, Bordeaux, France
| | - Antoine Fauconneau
- Department of Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Centre Hospitalo-Universitaire (CHU) de Bordeaux, Bordeaux, France
| | - Emilie Gérard
- Department of Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Centre Hospitalo-Universitaire (CHU) de Bordeaux, Bordeaux, France
| | - Lucile Boursault
- Department of Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Centre Hospitalo-Universitaire (CHU) de Bordeaux, Bordeaux, France
| | - Katia Boniface
- Inserm U1035, Biothérapie des Maladies Génétiques, Inflammatoires et Cancers (BMGIC), Immunodermatology team, University of Bordeaux, Bordeaux, France
| | - Anne-Sophie Darrigade
- Department of Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Centre Hospitalo-Universitaire (CHU) de Bordeaux, Bordeaux, France
| | - Julien Seneschal
- Department of Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, Centre Hospitalo-Universitaire (CHU) de Bordeaux, Bordeaux, France; Inserm U1035, Biothérapie des Maladies Génétiques, Inflammatoires et Cancers (BMGIC), Immunodermatology team, University of Bordeaux, Bordeaux, France.
| | | |
Collapse
|
21
|
Darrigade AS, Dendooven E, Mangodt E, Vermander E, Hagendorens M, Aerts O. A peculiar case of sensitization to Candelilla Cera and sucrose (di)stearate in a toddler. Contact Dermatitis 2019; 82:54-55. [PMID: 31400015 DOI: 10.1111/cod.13381] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2019] [Accepted: 08/09/2019] [Indexed: 11/26/2022]
Affiliation(s)
- Anne-Sophie Darrigade
- Department of Dermatology, Contact Allergy Unit, University Hospital Antwerp (UZA) and University of Antwerp (UA), Antwerp, Belgium
| | - Ella Dendooven
- Department of Dermatology, Contact Allergy Unit, University Hospital Antwerp (UZA) and University of Antwerp (UA), Antwerp, Belgium
| | - Evelyne Mangodt
- Department of Dermatology, Contact Allergy Unit, University Hospital Antwerp (UZA) and University of Antwerp (UA), Antwerp, Belgium
| | - Evert Vermander
- Department of Dermatology, Private Dermatologist, AZ Zeno, Blankenberge, Belgium
| | - Margo Hagendorens
- Department of Pediatrics, University Hospital Antwerp (UZA) and University of Antwerp (UA), Antwerp, Belgium
| | - Olivier Aerts
- Department of Dermatology, Contact Allergy Unit, University Hospital Antwerp (UZA) and University of Antwerp (UA), Antwerp, Belgium
| |
Collapse
|
22
|
Mascia P, Milpied B, Darrigade AS, Seneschal J, Eyraud A, Bonamonte D, Taïeb A. Azathioprine in combination with methotrexate: a therapeutic alternative in severe and recalcitrant forms of alopecia areata? J Eur Acad Dermatol Venereol 2019; 33:e494-e495. [PMID: 31374131 DOI: 10.1111/jdv.15834] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- P Mascia
- Department of Biomedical Science and Human Oncology, Section of Dermatology, University of Bari, Bari, Italy
| | - B Milpied
- Department of Dermatology and Pediatric Dermatology, National Centre for Rare skin Disorders, Hôpital Pellegrin-Enfants, CHU de Bordeaux, Bordeaux, France
| | - A S Darrigade
- Department of Dermatology and Pediatric Dermatology, National Centre for Rare skin Disorders, Hôpital Pellegrin-Enfants, CHU de Bordeaux, Bordeaux, France
| | - J Seneschal
- Department of Dermatology and Pediatric Dermatology, National Centre for Rare skin Disorders, Hôpital Pellegrin-Enfants, CHU de Bordeaux, Bordeaux, France
| | - A Eyraud
- Department of Dermatology and Pediatric Dermatology, National Centre for Rare skin Disorders, Hôpital Pellegrin-Enfants, CHU de Bordeaux, Bordeaux, France
| | - D Bonamonte
- Department of Biomedical Science and Human Oncology, Section of Dermatology, University of Bari, Bari, Italy
| | - A Taïeb
- Department of Dermatology and Pediatric Dermatology, National Centre for Rare skin Disorders, Hôpital Pellegrin-Enfants, CHU de Bordeaux, Bordeaux, France
| |
Collapse
|
23
|
Graille J, Blaizot R, Darrigade AS, Sainte-Marie D, Nacher M, Schaub R, Couppié P. Leprosy in French Guiana 2007-2014: a re-emerging public health problem. Br J Dermatol 2019; 182:237-239. [PMID: 31286485 PMCID: PMC6972665 DOI: 10.1111/bjd.18334] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- J Graille
- Dermatology Department, Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana
| | - R Blaizot
- Dermatology Department, Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana.,EA 3593, Ecosystèmes Amazoniens et Pathologies Tropicales, Université de Guyane, Cayenne, French Guiana
| | - A S Darrigade
- Dermatology Department, Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana
| | - D Sainte-Marie
- Dermatology Department, Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana
| | - M Nacher
- Centre d'Investigation Clinique, CIC INSERM 1424, Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana
| | - R Schaub
- Centre d'Investigation Clinique, CIC INSERM 1424, Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana
| | - P Couppié
- Dermatology Department, Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana.,EA 3593, Ecosystèmes Amazoniens et Pathologies Tropicales, Université de Guyane, Cayenne, French Guiana
| |
Collapse
|
24
|
Luherne C, Darrigade AS, Dutriaux C, Prey S, Milpied B. Reintroduction of dabrafenib after previous vemurafenib-induced DRESS: Not always safe! JAAD Case Rep 2019; 5:422-423. [PMID: 31061867 PMCID: PMC6488678 DOI: 10.1016/j.jdcr.2019.02.033] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Affiliation(s)
- Camille Luherne
- Saint André Hospital, University Hospital Center of Bordeaux, Bordeaux, France
| | | | - Caroline Dutriaux
- Saint André Hospital, University Hospital Center of Bordeaux, Bordeaux, France
| | - Sorilla Prey
- Saint André Hospital, University Hospital Center of Bordeaux, Bordeaux, France
| | - Brigitte Milpied
- Saint André Hospital, University Hospital Center of Bordeaux, Bordeaux, France
| |
Collapse
|
25
|
Lamoureux A, Meharon M, Durand AL, Darrigade AS, Doutre MS, Milpied B. A first case of erythema multiforme-like contact dermatitis caused by propolis. Contact Dermatitis 2018; 77:263-264. [PMID: 28872200 DOI: 10.1111/cod.12814] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Revised: 03/14/2017] [Accepted: 03/15/2017] [Indexed: 11/29/2022]
Affiliation(s)
- Anouck Lamoureux
- Dermatology Department, Saint André Hospital, 33075 Bordeaux, France
| | - Martine Meharon
- Dermatology Department, Saint André Hospital, 33075 Bordeaux, France
| | | | | | | | - Brigitte Milpied
- Dermatology Department, Saint André Hospital, 33075 Bordeaux, France
| |
Collapse
|
26
|
Goiset A, Darrigade AS, Labrèze C, Boralevi F, Milpied B. Aluminium sensitization in a French paediatric patch test population. Contact Dermatitis 2018; 79:382-383. [DOI: 10.1111/cod.13087] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Revised: 06/28/2018] [Accepted: 07/01/2018] [Indexed: 11/30/2022]
Affiliation(s)
- Anne Goiset
- Dermatology Department; Hôpital St André, CHU de Bordeaux; Bordeaux France
| | | | - Christine Labrèze
- Dermatology Department; Hôpital St André, CHU de Bordeaux; Bordeaux France
| | - Franck Boralevi
- Dermatology Department; Hôpital St André, CHU de Bordeaux; Bordeaux France
| | - Brigitte Milpied
- Dermatology Department; Hôpital St André, CHU de Bordeaux; Bordeaux France
| |
Collapse
|
27
|
Leroy V, Henrot P, Barnetche T, Cario M, Darrigade AS, Manicki P, Doutre MS, Lazaro E, Constans J, Barcat D, Vernhes JP, Richez C, Taieb A, Truchetet ME, Seneschal J. Association of skin hyperpigmentation disorders with digital ulcers in systemic sclerosis: Analysis of a cohort of 239 patients. J Am Acad Dermatol 2018; 80:478-484. [PMID: 30092330 DOI: 10.1016/j.jaad.2018.07.033] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2018] [Revised: 06/14/2018] [Accepted: 07/26/2018] [Indexed: 11/17/2022]
Abstract
BACKGROUND Skin pigmentation disorders in systemic sclerosis (SSc) have been sparsely described in the literature. Nevertheless, they could be a diagnostic and/or severity marker. OBJECTIVES To assess the association between pigmentation disorders and systemic involvement in patients with SSc. METHODS A total of 5 patterns of skin pigmentation disorders were defined: diffuse hyperpigmentation; hyperpigmentation of sun-exposed areas; hypopigmentation of the head, neck, and/or upper part of the chest; acral hypopigmentation; and diffuse hypopigmentation. RESULTS A total of 239 patients were included; 88 patients (36.8%) had skin pigmentation disorders as follows: diffuse hyperpigmentation and hyperpigmentation of sun-exposed areas in 38.6% (n = 34) and 27.3% (n = 24) of patients, respectively; hypopigmentation of the face, neck, and/or chest in 10.2% of patients (n = 9); diffuse hypopigmentation in 12.5% (n = 11); and acral hypopigmentation in 17% (n = 15). Diffuse hyperpigmentation was associated with diffuse SSc (P = .001), increased modified Rodnan skin score (P = .001), and shorter duration of Raynaud phenomenon (P = .002) in univariate analysis but not in multivariate analysis. Moreover, diffuse hyperpigmentation was associated with digital ulcers (P = .005), as confirmed by multivariate analysis (odds ratio, 2.96; 95% confidence interval, 1.28-6.89). LIMITATIONS This was a single-center retrospective study of a cohort of patients with SSc. CONCLUSION Screening for skin pigmentation disorders could be useful in the management of patients with SSc to identify those with a high risk of development of digital ulcers, which is a symptom of vascular involvement in SSc.
Collapse
Affiliation(s)
- Vaianu Leroy
- Department of Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France
| | - Pauline Henrot
- Department of Rheumatology, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France; Inserm U1035, Biothérapie des Maladies Génétiques et Cancers, University of Bordeaux, Bordeaux, France
| | - Thomas Barnetche
- Department of Rheumatology, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - Muriel Cario
- Inserm U1035, Biothérapie des Maladies Génétiques et Cancers, University of Bordeaux, Bordeaux, France
| | - Anne-Sophie Darrigade
- Department of Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France
| | - Pauline Manicki
- Department of Rheumatology, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - Marie-Sylvie Doutre
- Department of Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France
| | - Estibaliz Lazaro
- Department of Internal Medicine, Hôpital Haut-Levêque, CHU de Bordeaux, Bordeaux, France
| | - Joel Constans
- Department of Vascular Medicine, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France
| | - Damien Barcat
- Department of Internal Medicine, Hôpital Robert Boulin, Libourne, France
| | | | - Christophe Richez
- Department of Rheumatology, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France
| | - Alain Taieb
- Department of Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France; Inserm U1035, Biothérapie des Maladies Génétiques et Cancers, University of Bordeaux, Bordeaux, France
| | - Marie-Elise Truchetet
- Department of Rheumatology, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France; Immunoconcept, CNRS UMR 5164, Bordeaux University, Bordeaux, France
| | - Julien Seneschal
- Department of Dermatology, National Reference Center for Rare Skin Disorders, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France; Inserm U1035, Biothérapie des Maladies Génétiques et Cancers, University of Bordeaux, Bordeaux, France.
| |
Collapse
|
28
|
Eyraud A, Milpied B, Thiolat D, Darrigade AS, Boniface K, Taïeb A, Seneschal J. Inflammasome Activation Characterizes Lesional Skin of Folliculitis Decalvans. Acta Derm Venereol 2018. [PMID: 29542810 DOI: 10.2340/00015555-2924] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Folliculitis decalvans (FD) is a chronic inflammatory disease leading to scarring alopecia with poorly defined pathogenesis. The aim of this study was to investigate the expression of markers associated with the activation of innate immune signals, such as inflammasome (NALP1 and NALP3), interleukin (IL)-1β and IL-8 and type I interferon (MxA). A retrospective monocentric study was conducted and included 17 patients with FD with available biopsies. Disease activity (stable vs. active) was defined clinically and histologically. Immunostaining was performed using antibodies directed against NALP1, NALP3, IL-1β, IL-8, and MxA on FD skin biopsies. Results were compared with normal controls and lichen planopilaris. Eleven patients had active disease and 6 had stable disease. NALP1, NALP3, and IL-1β expression were significantly increased in hair follicles in FD compared with controls and lichen planopilaris. This study highlights the predominant immune signal associated with inflammasome activation in FD, suggesting the use of IL-1β blockade in FD.
Collapse
Affiliation(s)
- Alexia Eyraud
- Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin Disorders, Hôpital Saint-André, 1 rue Jean Burguet, FR-33075 Bordeaux Cedex, France
| | | | | | | | | | | | | |
Collapse
|
29
|
Braun V, Darrigade AS, Milpied B. Positive patch test reaction to carbamazepine after a very long delay. Contact Dermatitis 2018; 79:240-241. [DOI: 10.1111/cod.13031] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2018] [Revised: 04/04/2018] [Accepted: 04/19/2018] [Indexed: 11/27/2022]
Affiliation(s)
- Victoire Braun
- Department of Dermatology; Hopital Saint-André, CHU de Bordeaux; Bordeaux France
| | | | - Brigitte Milpied
- Department of Dermatology; Hopital Saint-André, CHU de Bordeaux; Bordeaux France
| |
Collapse
|
30
|
Dequidt L, Milpied B, Chauvel A, Seneschal J, Taieb A, Darrigade AS. A case of lichenoid and pigmented drug eruption to acetazolamide confirmed by a lichenoid patch test. J Allergy Clin Immunol Pract 2017; 6:283-285. [PMID: 28847654 DOI: 10.1016/j.jaip.2017.07.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Revised: 07/07/2017] [Accepted: 07/11/2017] [Indexed: 11/29/2022]
Affiliation(s)
- Laure Dequidt
- Department of Adult and Pediatric Dermatology, Bordeaux University Hospitals, Bordeaux, France
| | - Brigitte Milpied
- Department of Adult and Pediatric Dermatology, Bordeaux University Hospitals, Bordeaux, France.
| | - Annick Chauvel
- Department of Pathology, Bordeaux University Hospitals, Bordeaux, France
| | - Julien Seneschal
- Department of Adult and Pediatric Dermatology, Bordeaux University Hospitals, Bordeaux, France
| | - Alain Taieb
- Department of Adult and Pediatric Dermatology, Bordeaux University Hospitals, Bordeaux, France
| | - Anne-Sophie Darrigade
- Department of Adult and Pediatric Dermatology, Bordeaux University Hospitals, Bordeaux, France
| |
Collapse
|
31
|
Darrigade AS, Milpied B, Truchetet ME, Schaeverbeke T, Laharie D, Zerbib F, Beylot-Barry M, Jouary T, Taïeb A, Ezzedine K, Seneschal J. Pattern and Severity of Psoriasiform Eruptions in Patients with Inflammatory Bowel Diseases, Arthritis or Skin Inflammatory Disorders Treated with TNF-alpha Inhibitors. Acta Derm Venereol 2017; 97:731-734. [PMID: 28218339 DOI: 10.2340/00015555-2636] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Psoriasiform eruptions are a classical adverse skin reaction of tumour necrosis factor (TNF)-α inhibitors. The aim of this study was to identify the association between the severity or pattern of psoriasiform reactions and the underlying disease. A retrospective study was conducted between January 2012 and May 2015. Adult patients who developed psoriasiform eruptions whilst being treated with TNFα inhibitors were included. For each patient, 3 independent blinded dermatologists graded twice the severity of the lesions according to 6 clinical psoriasiform eruption types. Inter- and intra-individual kappa tests were performed to evaluate the robustness of the scoring system. The association between severity score levels or the pattern of reactions and the underlying disease was assessed. The severity scoring system showed good inter- and intra-observer reproducibility. Women patients treated with TNFα inhibitors for inflammatory bowel diseases showed a higher risk of developing severe reactions with scalp and skin-fold involvement.
Collapse
Affiliation(s)
- Anne-Sophie Darrigade
- Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin Disorders, Saint-André Hospital, Bordeaux, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Boukhedouni N, Jacquemin C, Darrigade AS, Dessarthe B, Rambert J, Thiolat D, Lucchese F, Bertolotti A, Taieb A, Ezzedine K, Seneschal J, Boniface K. Rôle des lymphocytes T effecteurs mémoires CD4+ et CD8+ CXCR3+ dans la perte du mélanocyte au cours du vitiligo. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
33
|
Darrigade AS, Vedie AL, Gauthier C, Cario-André M, Taieb A, Truchetet ME, Constans J, Seneschal J. Pigmented skin patches without scleroderma as a predominant clinical symptom revealing systemic sclerosis. Clin Exp Dermatol 2015; 41:379-82. [PMID: 27171356 DOI: 10.1111/ced.12752] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/19/2015] [Indexed: 11/26/2022]
Abstract
Skin induration remains the major clinical symptom of systemic sclerosis (SSc), an autoimmune disease with potentially life-threatening visceral involvement. However, skin induration can be absent in some patients, making the diagnosis difficult to confirm and leading to delay in management. Skin pigmentation abnormalities have been reported in patients with SSc, and can be important to recognize for diagnosis. We report two patients who developed hyperpigmented skin patches without any sign of scleroderma, as a major clinical skin symptom of incipient SSc.
Collapse
Affiliation(s)
- A S Darrigade
- Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin Disorders, Hôpital Saint André, Bordeaux, France
| | - A L Vedie
- Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin Disorders, Hôpital Saint André, Bordeaux, France
| | - C Gauthier
- Department of Vascular Medicine, Hôpital Saint André, Bordeaux, France
| | - M Cario-André
- INSERM U1035, University of Bordeaux, Bordeaux, France
| | - A Taieb
- Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin Disorders, Hôpital Saint André, Bordeaux, France.,INSERM U1035, University of Bordeaux, Bordeaux, France
| | - M E Truchetet
- Department of Rheumatology, Hôpital Pellegrin, Bordeaux, France
| | - J Constans
- Department of Vascular Medicine, Hôpital Saint André, Bordeaux, France
| | - J Seneschal
- Department of Dermatology and Pediatric Dermatology, National Centre for Rare Skin Disorders, Hôpital Saint André, Bordeaux, France.,INSERM U1035, University of Bordeaux, Bordeaux, France
| |
Collapse
|